BIIB 092

Drug Profile

BIIB 092

Alternative Names: Anti-eTau; BIIB092; BMS-986168; IPN-007

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iPierian
  • Developer Bristol-Myers Squibb; iPierian
  • Class Monoclonal antibodies; Neuropsychotherapeutics
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Progressive supranuclear palsy
  • Discontinued Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 24 Apr 2017 Phase-II clinical trials in Progressive supranuclear palsy in USA (IV) (NCT03068468)
  • 13 Apr 2017 Biogen plans a phase II trial for Alzheimer’s disease
  • 13 Apr 2017 BIIB 092 licensed to Biogen worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top